Literature DB >> 28361440

Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Leon Fisher1, Alexander Fisher2,3.   

Abstract

This narrative review summarises the benefits, risks and appropriate use of acid-suppressing drugs (ASDs), proton pump inhibitors and histamine-2 receptor antagonists, advocating a rationale balanced and individualised approach aimed to minimise any serious adverse consequences. It focuses on current controversies on the potential of ASDs to contribute to infections-bacterial, parasitic, fungal, protozoan and viral, particularly in the elderly, comprehensively and critically discusses the growing body of observational literature linking ASD use to a variety of enteric, respiratory, skin and systemic infectious diseases and complications (Clostridium difficile diarrhoea, pneumonia, spontaneous bacterial peritonitis, septicaemia and other). The proposed pathogenic mechanisms of ASD-associated infections (related and unrelated to the inhibition of gastric acid secretion, alterations of the gut microbiome and immunity), and drug-drug interactions are also described. Both probiotics use and correcting vitamin D status may have a significant protective effect decreasing the incidence of ASD-associated infections, especially in the elderly. Despite the limitations of the existing data, the importance of individualised therapy and caution in long-term ASD use considering the balance of benefits and potential harms, factors that may predispose to and actions that may prevent/attenuate adverse effects is evident. A six-step practical algorithm for ASD therapy based on the best available evidence is presented.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28361440     DOI: 10.1007/s40261-017-0519-y

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  749 in total

Review 1.  The effect of proton pump inhibitors on the human microbiota.

Authors:  B J Vesper; A Jawdi; K W Altman; G K Haines; L Tao; J A Radosevich
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

2.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

Review 3.  Probiotics for preventing ventilator-associated pneumonia.

Authors:  Lulong Bo; Jinbao Li; Tianzhu Tao; Yu Bai; Xiaofei Ye; Richard S Hotchkiss; Marin H Kollef; Neil H Crooks; Xiaoming Deng
Journal:  Cochrane Database Syst Rev       Date:  2014-10-25

Review 4.  Strongyloidiasis: a conundrum for gastroenterologists.

Authors:  D I Grove
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

5.  Colonization pattern of the digestive tract by potentially pathogenic microorganisms: colonization-controlling mechanisms and consequences for antibiotic treatment.

Authors:  D van der Waaij
Journal:  Infection       Date:  1983       Impact factor: 3.553

6.  Cimetidine therapy and duodenal candidiasis: role in healing process.

Authors:  S Singh; N Singh; R Kochhar; P Talwar; S K Mehta
Journal:  Indian J Gastroenterol       Date:  1992-01

Review 7.  Current trends in research into the waterborne parasite Giardia.

Authors:  Samantha Lane; David Lloyd
Journal:  Crit Rev Microbiol       Date:  2002       Impact factor: 7.624

Review 8.  Tumor acidity, chemoresistance and proton pump inhibitors.

Authors:  Angelo De Milito; Stefano Fais
Journal:  Future Oncol       Date:  2005-12       Impact factor: 3.404

9.  Gut microbiota-mediated drug interactions between lovastatin and antibiotics.

Authors:  Dae-Hyoung Yoo; In Sook Kim; Thi Kim Van Le; Il-Hoon Jung; Hye Hyun Yoo; Dong-Hyun Kim
Journal:  Drug Metab Dispos       Date:  2014-06-19       Impact factor: 3.922

Review 10.  Immunomodulation by gut microbiota: role of Toll-like receptor expressed by T cells.

Authors:  Mariagrazia Valentini; Alessia Piermattei; Gabriele Di Sante; Giuseppe Migliara; Giovanni Delogu; Francesco Ria
Journal:  J Immunol Res       Date:  2014-07-24       Impact factor: 4.818

View more
  9 in total

1.  Proton pump inhibitor use and cancer mortality.

Authors:  Siri A Tvingsholm; Christian Dehlendorff; Kell Østerlind; Søren Friis; Marja Jäättelä
Journal:  Int J Cancer       Date:  2018-05-02       Impact factor: 7.396

2.  An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19.

Authors:  Jan Homolak; Ivan Kodvanj; Vladimir Trkulja
Journal:  Clin Drug Investig       Date:  2021-02-19       Impact factor: 2.859

Review 3.  The interplay between Helicobacter pylori and the gut microbiota: An emerging driver influencing the immune system homeostasis and gastric carcinogenesis.

Authors:  Farzaneh Fakharian; Behnoush Asgari; Ali Nabavi-Rad; Amir Sadeghi; Neda Soleimani; Abbas Yadegar; Mohammad Reza Zali
Journal:  Front Cell Infect Microbiol       Date:  2022-08-15       Impact factor: 6.073

4.  Association between Acid-Suppressive Drugs and Clinical Outcomes in Patients with Nonvalvular Atrial Fibrillation.

Authors:  Hideki Arai; Shinichiro Ueda; Kazutaka Uchida; Fumihiro Sakakibara; Norito Kinjo; Mari Nezu; Takeshi Morimoto
Journal:  Drugs R D       Date:  2022-07-19

5.  Association between Urolithiasis and History Proton Pump Inhibitor Medication: A Nested Case-Control Study.

Authors:  So Young Kim; Dae Myoung Yoo; Woo Jin Bang; Hyo Geun Choi
Journal:  J Clin Med       Date:  2022-09-26       Impact factor: 4.964

Review 6.  Gastric microbiota: tracing the culprit.

Authors:  Cristian Vasile Petra; Aronel Rus; Dan Lucian Dumitraşcu
Journal:  Clujul Med       Date:  2017-10-20

Review 7.  The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid.

Authors:  Tom C Martinsen; Reidar Fossmark; Helge L Waldum
Journal:  Int J Mol Sci       Date:  2019-11-29       Impact factor: 5.923

Review 8.  Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?

Authors:  Bruno Charpiat; Nathalie Bleyzac; Michel Tod
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859

9.  Community-dwelling older adults' awareness of the inappropriate use of proton pump inhibitors.

Authors:  Mohammad Rababa; Abeer Rababa'h
Journal:  BMC Geriatr       Date:  2020-10-29       Impact factor: 3.921

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.